top of page

Low-Grade Glioma in Adults: Monitoring, Surgery and Getting a Second Opinion

8 hours ago
6 min read
A model of the human brain cut in half, with one area shaded purple

A low-grade glioma is a slow-growing brain tumour that starts in the brain's supporting (glial) cells. Not everyone needs an operation straight away, but the decision between watching and operating is one of the most debated in brain tumour care, and it deserves a careful, unhurried discussion with a specialist team. Here I explain what the diagnosis means, what the evidence says about monitoring versus early surgery, and when a second opinion is worth asking for.


In brief

  • Grade 2 gliomas are low grade and usually grow slowly, but they can sometimes be cancerous and need specialist follow-up [1][2].

  • Some people can be monitored with regular MRI scans, especially when the tumour causes no symptoms [1][8].

  • A large non-randomised Norwegian study found higher five-year survival at a centre that favoured early surgery (74% versus 60%) [4].

  • Vorasidenib, a targeted tablet for IDH-mutant grade 2 glioma, delayed progression in a phase 3 trial and was approved by the UK regulator in September 2025 [7][9].


What does "low grade" mean?

Brain tumours are graded from 1 to 4. Grades 1 and 2 are called low grade and grades 3 and 4 high grade; gliomas can be either low grade (grade 2) or high grade [2]. The NHS describes low-grade tumours as usually growing slowly and being less likely to spread, but it also notes that a glioma can sometimes be cancerous [1]. That is why "low grade" is not the same as "harmless", and why follow-up matters even when no treatment is needed yet.

Since 2021, the World Health Organization classification has relied much more on molecular tests of the tumour tissue alongside how it looks under the microscope [3]. In practice, your pathology report will include results such as whether the tumour carries an IDH mutation, which now shapes both the diagnosis and some treatment options [3][7].


What symptoms lead to the diagnosis?

In my experience, many people are diagnosed after a first seizure. Other symptoms listed by the NHS include headaches that get worse over time or do not go away, feeling sick, changes in eyesight, changes in behaviour, memory or concentration, and problems with speech, movement or balance [1]. Some low-grade gliomas are found by chance on a scan done for another reason.


Is it safe to monitor a low-grade glioma?

Sometimes. The NHS notes that you may not need treatment straight away [1], and that if a very slow-growing tumour is not causing symptoms, surgery may not be needed immediately [8]. Monitoring means regular MRI scans and clinic reviews, with a plan for what change on the scan would prompt treatment.

The case for earlier surgery comes mainly from a Norwegian study that compared two hospitals with different policies [4]. One centre favoured biopsy and watchful waiting; the other favoured early removal of the tumour. Among 153 adults, estimated five-year survival was 60% at the watchful-waiting centre and 74% at the early-resection centre [4]. This was not a randomised trial: patients were treated according to where they lived, so other differences between the centres may have played a part [4]. Even so, it has strongly influenced how neurosurgeons think about timing.

In my view, the decision depends on where the tumour sits, how it is affecting you, how much of it can be removed safely, and what matters most to you. In my own practice, I favour an early biopsy to confirm the diagnosis, and when the tumour is accompanied by swelling (oedema) in the surrounding brain, I usually recommend surgery, based on my experience.


What can surgery achieve?

Surgery aims to confirm the exact diagnosis and to remove as much of the tumour as is safely possible. How much is removed may matter for everyday life as well as survival. In a review of seven observational studies (234 people), return to work within a year was reported in 84% after complete (gross total) removal, 66% after subtotal removal and 31% after partial removal [5]. The numbers are small and the confidence intervals wide, so these figures are a guide rather than a prediction [5].

When a tumour lies close to areas that control speech or movement, I use brain mapping during the operation and, where it helps, awake surgery, so that these functions can be checked while the tumour is removed.


What happens after surgery?

Not everyone needs further treatment immediately. Decisions about radiotherapy and drug treatment are made together with our oncology team. For those who need further treatment, the options depend on the tumour type and how much remains:

  • Radiotherapy plus chemotherapy. In a long-term randomised trial of 251 people with higher-risk low-grade glioma, adding a chemotherapy combination (PCV) to radiotherapy increased median overall survival from 7.8 to 13.3 years [6].

  • Targeted treatment. In a phase 3 trial of 331 people with residual or recurrent grade 2 IDH-mutant glioma who had only had surgery, the tablet vorasidenib extended median progression-free survival to 27.7 months, compared with 11.1 months with placebo [7]. Serious side effects were more common with vorasidenib (22.8% versus 13.5%), mainly raised liver enzymes [7]. In the UK, the medicines regulator (MHRA) approved vorasidenib in September 2025 for people aged 12 and over with a grade 2 astrocytoma or oligodendroglioma carrying an IDH1 or IDH2 mutation who do not need immediate chemotherapy or radiotherapy after surgery [9]. Whether it is offered to you on the NHS also depends on NICE or Scottish Medicines Consortium decisions, so ask your oncology team.

After treatment, you will have regular check-ups and scans for years, because a tumour can come back or change [1].


Why get a second opinion?

Because there is no single right answer for every low-grade glioma, it is reasonable to ask for a second opinion, particularly when you are offered watchful waiting, or when you are told the tumour cannot be removed safely. A neurosurgeon who reviews your MRI and pathology report may see the balance of risks differently.

If you are in the UK, your NHS specialist team remains central to your care. You can read how a neurosurgical second opinion using your NHS MRI works, and what to expect from brain tumour surgery in Turkey if you are considering it. My approach to brain tumours is described on a separate page.

In the UK, you must tell the DVLA if you have a brain tumour [1].


When to see a doctor

Call 999 if [1]:

  • you have a headache that came on suddenly and is extremely painful

  • someone has a seizure (fit) for the first time

Ask for an urgent GP appointment or contact NHS 111 if [1]:

  • you keep getting headaches, they do not go away or they are getting worse

  • you have headaches that wake you up at night or are worse in the morning

  • you have any other symptoms of a brain tumour that do not go away

If you are already being monitored for a low-grade glioma, contact your specialist team about new seizures, new weakness or speech problems, or a clear change in your symptoms.


FAQ

Is a low-grade glioma cancer?

Grade 2 gliomas are classed as low grade and usually grow slowly, but the NHS notes that gliomas can sometimes be cancerous [1][2]. They need specialist follow-up even when no treatment is given.


Can a low-grade glioma just be watched?

For some people, yes, especially when it causes no symptoms [1][8]. A large non-randomised study found better survival at a centre that favoured early surgery [4], so the choice should be made with a specialist team.


Does removing more of the tumour help?

In observational studies, people who had complete removal were more likely to return to work within a year [5]. How much can be removed safely depends on the tumour's location.


Are there new drug treatments?

Vorasidenib, a targeted tablet for IDH-mutant grade 2 glioma, delayed progression in a phase 3 trial [7]. Whether it suits you depends on the tumour's molecular profile and previous treatment.



Send me your MRI for a review

If you would like me to look at your scans, you can send me your MRI for a review on WhatsApp. A review of images is not a full assessment, which also needs your history and an examination. I am a neurosurgeon at my own clinic in Izmir, Turkey, working with our oncology team; I work alongside your NHS care, not instead of it.



Written by Kaan Tugberk Ozdemir, MD — Neurosurgeon | Izmir, Türkiye · Last updated: November 2026. This article is for general information and does not replace a consultation.


Sources

  1. NHS. Non-cancerous (benign) brain tumours. Page last reviewed: 27 February 2025. Accessed: 14 November 2026.

  2. NHS. Brain tumours. Page last reviewed: 12 June 2023. Accessed: 14 November 2026.

  3. Louis DN, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 2021;23(8):1231-1251.

  4. Jakola AS, et al. Comparison of a strategy favoring early surgical resection vs a strategy favoring watchful waiting in low-grade gliomas. JAMA. 2012;308(18):1881-8.

  5. Elsheikh M, et al. Association of extent of resection and functional outcomes in diffuse low-grade glioma: systematic review & meta-analysis. J Neurooncol. 2022;160(3):717-724.

  6. Buckner JC, et al. Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma. N Engl J Med. 2016;374(14):1344-55.

  7. Mellinghoff IK, et al. Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma. N Engl J Med. 2023;389(7):589-601.

  8. NHS. Malignant brain tumour (brain cancer) — Treatment. Page last reviewed: 9 April 2025. Accessed: 14 November 2026.

  9. Medicines and Healthcare products Regulatory Agency. Vorasidenib approved to treat patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation. GOV.UK, 16 September 2025. Accessed: 18 November 2026.


Comments


Contact & Appointments

For appointments and enquiries, please call us or use the contact form.

​

Phone / WhatsApp

+90 532 311 40 95

E-mail

drtugberkozdemir@gmail.com

Send Us a Message

© 2026 Dr. Kaan Tugberk Ozdemir

bottom of page
WhatsApp